Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sonnet BioTherapeutics Holdings ( (SONN) ) just unveiled an update.
Sonnet BioTherapeutics Holdings, a company involved in the biopharmaceutical industry, has announced changes in its executive leadership following the passing of its President, CEO, and Chairman, Pankaj Mohan, on March 31, 2025. Raghu Rao, a current board member with extensive experience in high-technology companies and government contracts, has been appointed as interim CEO. Additionally, Stephen McAndrew, previously the Chief Business Officer, has been promoted to President and Chief Business Officer. These leadership changes are expected to influence the company’s strategic direction and operations.
More about Sonnet BioTherapeutics Holdings
YTD Price Performance: -16.25%
Average Trading Volume: 140,669
Technical Sentiment Signal: Buy
Current Market Cap: $4.11M
For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.